Product Suite

AI Powered Solutions for teams at Pharma.

Five products that take life-sciences teams from systematic literature review to a board-ready value story, on one connected platform.

Meet usISPOR Europe 2026Austria Center Vienna / Booth #819 / Nov 8-11, 2026

01 / 05

Accelerating Evidence.

Bespoke and a fully AI-integrated systematic review tool. Search, screening, extraction, and synthesis based on full text.

01Customisable forms and processes
02Invite and collaborate
03AI functionality when needed
04Smooth free full-text procurement
05Your evidence repository
06Immediate efficiency

Accelerating Evidence

Get Started

Built by researchers, for reviewers

Accelerating Evidence

Made for reviewers, by reviewers

HomeAccess OptionsFeaturesAbout UsContactDocs

Sign upLogin

Get Started

Screening / Bulk

Search keywords

Screened 0 / 2,201

IDTitleDecision

507541Immunotherapy outcomes in advanced non-small cell lung cancerPendingInclude

507542Real-world adherence to biologic therapy in plaque psoriasisPendingExclude

507543Cost-effectiveness of SGLT2 inhibitors in heart failurePendingInclude

507544Long-term outcomes of dopamine agonists in Parkinson's diseasePendingExclude

507545Quality of life after CAR-T therapy: a cohort studyPending

Reports

Decisions

0studies

IncludeExcludeUncertain

Decisions per hour

Reviewer A

Reviewer B

AI assist

Conflicts

Pending

Studies screened

Included

Decisions / hour

Augment

Human→AI→Result

Not a black box. AI working alongside the researcher at every step.

PLUS

New Rapid Review

QuestionPICOSSearchUploadReview

PPopulation

Adults with advanced NSCLC

IIntervention

Systemic immunotherapy

CComparator

Platinum chemotherapy

OOutcomes

Overall and progression-free survival

SStudy design

Randomised controlled trials

BackGenerate search →

Refine PICOS with AI

Focus on late-stage patients only.

Ask AI to refine...

Building your PubMed search query

0 studies found for this query

Step 4: Results

Screening 405 abstracts with AIRunning batches... Complete

Screened

Included

Uncertain

Excluded

Decisions tablePRISMA diagramSummary

INCLUDEImmunotherapy outcomes in advanced non-small cell lung cancer2019

EXCLUDEReal-world adherence to biologic therapy in plaque psoriasis2020

UNCERTAINCost-effectiveness of SGLT2 inhibitors in heart failure2021

INCLUDELong-term outcomes of dopamine agonists in Parkinson's disease2022

EXCLUDEQuality of life after CAR-T therapy: a cohort study2023

Accelerating Evidence

Get Started

Everything you love,

still free.

And now, even more...

with ActiveSLR Plus

02 / 05

Perform a Targeted Literature Review in minutes.

ActiveTLR breaks every targeted literature review into discrete, transparent steps. At each stage, you have the opportunity to review and edit before moving on, keeping you in control throughout.

01Precision AI retrieval
02Cross-database deduplication
03AI screening & full-text retrieval
04AI-driven data extraction
05Team workspaces & folders

AI-powered targeted literature review

From a clinical question to decision-ready evidence.

Precision evidence. Faster.

ACTIVETLR.COM

A question becomes a review.

A transparent, guided workflow, with you in control.

Ask your question

Plain language → PICOS, PICOC, PEO, PFO or CoCoPop

Build a search

A reviewable PubMed strategy, tailored to your framework

Deduplicate records

Bring sources together. Identify duplicates in seconds.

Screen with AI

Criteria-based decisions, with a rationale you can inspect

Extract and synthesise

Structured evidence and a narrative summary, ready to review

Built for pharma, biotech and CRO evidence teams

Search strategy

Your clinical question

What is the clinical effectiveness of targeted therapies in adults with advanced non-small cell lung cancer?

PubMed search strategy

("NSCLC" OR "non-small cell lung cancer") AND (targeted therapy OR treatment) AND (efficacy OR survival)

PubMed · 1,842Embase · 1,106Imported · 320

Records gathered0

Cross-database matching

Duplicates resolved

AI screening

Transparent criteria. Reviewable decisions.

Title & abstract

RecordStudy titleAI decision

AT-104Targeted therapy outcomes in advanced NSCLCInclude

AT-105Patient-reported outcomes in oncology careExclude

AT-106Real-world survival with kinase inhibitors: a cohort studyInclude

AT-107A review of unrelated surgical interventionsExclude

Reviewer stays in control · Inspect or override any decision

From included studies to useful insight.

AI-assisted extraction: structured, traceable and editable.

Extraction fieldEvidence

PopulationAdults, stage III–IV↗ source

InterventionTargeted therapy↗ source

ComparatorStandard of care↗ source

OutcomeOverall survival↗ source

Study designRandomised trial↗ source

Evidence synthesis

Across included studies, outcomes suggest a consistent effect in the target population. Review the source evidence and contextualise findings before drawing conclusions.

Population & setting

Effectiveness

Quality of life

Every extracted value can be traced back to its source.

Transparent by design.

A clear audit trail across every step of your review.

01Documented methods and search strategy

02Inclusion / exclusion rationale

03Study selection flow diagram

04Versioned edits and reviewer decisions

Hours, not weeks.

Targeted literature reviews, powered by AI and guided by experts.

Explore ActiveTLR

WWW.ACTIVETLR.COM

03 / 05

Automated evidence synthesis.

Streamline your evidence synthesis workflows with an intelligent platform designed for and used by practitioners. Shorten time-to-decision and charge up your evidence strategy.

01Visualise networks
02Feasibility analysis
03Network Meta Analysis
04Scenario Comparison
05Rankings & SUCRA
06Model Diagnostics

Networks

Feasibility

Meta-analysis

Rankings

Network meta-analysis, automated.

New analysis

Set up your analysis

Bring your trial data; HeliQ proposes the model.

Outcome

Overall survival (HR)

Reference

Placebo

Evidence

14 RCTs · 5 treatments

Model

Bayesian, random effects

AI assistant

Build network →

Model configured

Analysis / Network

Evidence network0 trials · 5 treatments

Feasibility checks

Network connected

Comparable populations

Consistency (node-split)

Heterogeneity: moderate

Run feasibility

Network is feasible for NMA

Results / Network meta-analysis

Compare every treatment at once

Hazard ratio vs placebo with 95% credible interval

TREATMENTHAZARD RATIOHR (95% CrI)0.50.7511.25

Treatment A0.68 (0.55, 0.84)

Treatment B0.79 (0.64, 0.97)

Treatment C0.91 (0.70, 1.18)

Treatment D0.74 (0.58, 0.95)

Convergence

R̂ = 1.00

Model fit

DIC 0

Inconsistency

p = 0.42

Results / Rankings

Rank treatments with confidence

SUCRA: probability of being among the best, across the network

SUCRA rankingHigher is better

1Treatment A0%

2Treatment D0%

3Treatment B0%

4Treatment C0%

5Placebo0%

Scenario comparison

Base case · random effects

Treatment A ranks 1st

Fixed effect

Ranking unchanged

Excluding high risk of bias

Treatment A ranks 1st

Compare scenarios

Report ready to export

Every comparison,
one network.

AI-enabled network meta-analysis
for efficient evidence synthesis.

Explore HeliQ ↗

heliq.io

04 / 05

Automated Health Economic Modelling.

Create Health Economic Models in hours with AI Automated platform designed for developing cost-effectiveness and budget impact models for key HTA and non-HTA markets.

01Develop Model Specification
02Create Model Structure
03Research Model Inputs
04Create Dashboards from Model Results
05Conduct Sensitivity Analyses
06Conduct Scenario Analysis

ModeLynx · model_inputs.xlsx • Saved

FileHomeInsertDataFormulasView Find

E12

Cohort

Treatment

Comparator

Cost

Effect

Cohort A

Therapy X

Standard care

£18,420

8.42

Cohort B

Therapy X

Standard care

£21,150

9.08

Cohort C

Therapy Y

Standard care

£16,880

7.96

Cohort D

Therapy Y

Standard care

£19,320

8.71

Cohort E

Therapy X

Standard care

£22,040

9.31

InputsAssumptionsOutputs

Your data. Your workflow.

A familiar spreadsheet-style way to work with structured inputs.

Data ready

Data in. Insight out.

A grid is just the beginning.

Same inputs, now a model you can see and run.

StateCost / cycleUtilityStable£1,2400.82Progressed£3,9800.61Death£00.00

Stable£1,240 · u 0.82

Progressed£3,980 · u 0.61

Death£0 · u 0.00

Run model

0 cycles run · ICER £21,870 per QALY gained

The signal, made visible.

Illustrative data visualisation workspace

Model runs

Cost-effectiveness

ICER

Compare the trade-off

Analysis status

Ready to explore

Compare treatment pathways

Therapy X

Therapy Y

Standard care

Outcome trajectory

Evidence-informed

Explore scenarios

See more than rows and columns.

What if the assumptions change?

A scenario is a question worth exploring.

Treatment cost£18,420

LowerHigher

Effect uncertainty8%

NarrowWide

Scenario comparison

Therapy X

Therapy Y

Standard care

Compare the impact of assumptions

Explore the range. Understand the decision.

Health economic modelling,

rebuilt.

A new way to work with data, models, and outcomes.

Something exciting is coming soon

www.modelynx.com

05 / 05

Personalised value stories.

Enable pharma companies to engage payers in a personalised way, updating them with the latest data and adapting the conversation to their evolving needs by reducing delays, minimises misunderstandings, and ensures that the value proposition is communicated in the most relevant manner possible.

01Shareable
02Productivity Savings
03Payer/HTA Ready Dashboards
04Rapid Iteration & Updates
05Visually Appealing
06User-Driven
07Intuitive user-interface

MAKE VALUE VISIBLE

Turn complex information into a story that moves people.

One story. Every stakeholder.

Operations

Leadership

Finance

Align teams around the value that matters.

Too complicated?

Impact_analysis_final_v7.xlsx

MetricBaselineCurrentDeltaRevenue$1.8M$2.4M+33%Costs$920K$840K−9%Hours4,2002,850−32%ROI2.1x4.8x+129%

What is the
real impact?

Too many cells. Not enough clarity.

From numbers to narrative

Raw data

Revenue impact$2.4M

Cost savings$840K

Efficiency gain32%

Value impact at a glance

Q1Q2Q3Q4

A clear picture of the value you create.

VALUE STORY / OVERVIEW

Revenue impact

$0M

↑ value created

Efficiency gain

↑ time returned

Return on value

↑ measurable impact

Impact over time

Value mix

100%

● Impact● Cost

Insight: value is growing quarter over quarter.

SECURE

Clear insights

Confident decisions

Stories worth sharing

Make the important things easier to see and share.

Make your value impossible to miss.

From complex data to clear, compelling stories.

valuestory.io

Get in touch

Schedule a meeting.

Stay up to date with the latest news, announcements, and articles